O.N. Diagnostics

Executive Summary

O.N. Diagnostics is a US-based medical technology company that has developed a groundbreaking bone health diagnostic platform. Its core technology, Biomechanical Computed Tomography (BCT), analyzes routine CT scans to provide not only bone mineral density measurements but also a direct assessment of bone strength, offering a more comprehensive evaluation of fracture risk than traditional DXA scans. The company's flagship product, VirtuOst, is an FDA-cleared virtual stress test for bone that aids in the diagnosis of osteoporosis, fracture risk assessment, and treatment monitoring. Founded in 2005 and based in Berkeley, California, O.N. Diagnostics addresses a significant unmet need in the osteoporosis diagnostics market, where current methods often fail to capture bone quality. The platform's ability to leverage existing CT infrastructure positions it for scalable adoption in both clinical and research settings, potentially reducing the burden of osteoporotic fractures, a major cause of morbidity and healthcare costs.

Upcoming Catalysts (preview)

• Q3 2026Expansion of FDA clearance for additional clinical indications (e.g., monitoring therapy response in specific patient populations)65% success
• Q4 2026Strategic partnership or licensing deal with a major imaging equipment manufacturer or healthcare system to broaden distribution50% success
• Q2 2026Publication of landmark clinical study demonstrating superiority of BCT over DXA for fracture prediction in a large cohort75% success